Literature DB >> 33755867

Unnecessary Abdominal Surgeries in Attacks of Hereditary Angioedema with Normal C1 Inhibitor.

Marcel Gutierrez1, Camila L Veronez2,3, Solange O Rodrigues Valle4, Rozana Fátima Gonçalves5, Mariana Paes Leme Ferriani6, Adriana S Moreno6, L Karla Arruda6, Marcelo Vivolo Aun7,8, Pedro Giavina-Bianchi7, Maria Luiza Oliva Alonso4, Joao B Pesquero9, Anete S Grumach10.   

Abstract

Hereditary angioedema (HAE) is an autosomal dominant disease mostly due to the deficiency of C1 inhibitor (C1-INH). HAE with normal C1-INH was first described in 2000 and associated with mutations in the coagulation factor XII in 2006. Both diseases are associated with high bradykinin production, resulting in increased vascular permeability. Gastrointestinal edema due to HAE can be misdiagnosed as acute abdomen and unnecessary surgical procedures may be performed. The present study evaluates the prevalence of surgical procedures and/or acute abdomen in HAE patients with the coagulation factor XII mutation. It is a retrospective study where patients were diagnosed with recurrent angioedema without urticaria, normal C1-INH levels, and positive family history of angioedema. All patients were evaluated for the known mutations located at exon 9 of the F12 gene. Medical records were evaluated and questionnaires were applied to 52 patients with normal C1-INH levels (age range 13-76 years; 47/52, 90.38% women; 5/52, 9.61% men). F12 mutation was present in 32/52 patients (61.5%). Acute abdominal pain was diagnosed in 16/52 (30.76%) patients, appendicitis in 9/16 (56.2%), and undetermined diagnosis in 7/16 (43.7%). Among patients diagnosed with acute abdominal pain, 13/16 (81.2%) underwent surgery and 3/16 (18.7%) improved without surgical intervention. We conclude that many HAE patients with coagulation factor XII mutation were misdiagnosed with acute abdomen and subjected to unnecessary invasive procedures. It is critical to disseminate information about this rare mutation in patients with otherwise normal C1-INH activity, in order to speed up diagnosis and avoid misconduct.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute abdomen; C1 inhibitor; F12 mutation; Hereditary angioedema; Surgery

Mesh:

Substances:

Year:  2021        PMID: 33755867     DOI: 10.1007/s12016-021-08852-7

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  14 in total

1.  Angioedema without urticaria: novel findings which must be measured in clinical setting.

Authors:  Camila Lopes Veronez; Anete Sevciovic Grumach
Journal:  Curr Opin Allergy Clin Immunol       Date:  2020-06

2.  Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations.

Authors:  K Bork; K Wulff; G Witzke; J Hardt
Journal:  Allergy       Date:  2015-05-22       Impact factor: 13.146

3.  A rare mutation in the F12 gene in a patient with ACE inhibitor-induced angioedema.

Authors:  Camila Lopes Veronez; Faradiba Sarquis Serpa; João Bosco Pesquero
Journal:  Ann Allergy Asthma Immunol       Date:  2017-05-05       Impact factor: 6.347

Review 4.  Hereditary Angioedema.

Authors:  Paula J Busse; Sandra C Christiansen
Journal:  N Engl J Med       Date:  2020-03-19       Impact factor: 91.245

5.  Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?

Authors:  Michael L Lunn; Carah B Santos; Timothy J Craig
Journal:  Ann Allergy Asthma Immunol       Date:  2010-03       Impact factor: 6.347

6.  Meeting the challenges and burdens associated with hereditary angioedema.

Authors:  Michael Toscani; Marc Riedl
Journal:  Manag Care       Date:  2011-09

7.  Hereditary angioedema: first report of the Brazilian registry and challenges.

Authors:  A S Grumach; S O R Valle; E Toledo; D de Moraes Vasconcelos; M M S Villela; E Mansour; J A Pinto; R A Campos; A T França
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-08-07       Impact factor: 6.166

8.  Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency.

Authors:  Konrad Bork; Petra Staubach; Alexander J Eckardt; Jochen Hardt
Journal:  Am J Gastroenterol       Date:  2006-02-08       Impact factor: 10.864

Review 9.  8. Hereditary angioedema.

Authors:  Michael M Frank
Journal:  J Allergy Clin Immunol       Date:  2008-02       Impact factor: 10.793

10.  Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence.

Authors:  Konrad Bork; Thomas Machnig; Karin Wulff; Guenther Witzke; Subhransu Prusty; Jochen Hardt
Journal:  Orphanet J Rare Dis       Date:  2020-10-15       Impact factor: 4.123

View more
  1 in total

1.  The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Authors:  Marcus Maurer; Markus Magerl; Stephen Betschel; Werner Aberer; Ignacio J Ansotegui; Emel Aygören-Pürsün; Aleena Banerji; Noémi-Anna Bara; Isabelle Boccon-Gibod; Konrad Bork; Laurence Bouillet; Henrik Balle Boysen; Nicholas Brodszki; Paula J Busse; Anette Bygum; Teresa Caballero; Mauro Cancian; Anthony J Castaldo; Danny M Cohn; Dorottya Csuka; Henriette Farkas; Mark Gompels; Richard Gower; Anete S Grumach; Guillermo Guidos-Fogelbach; Michihiro Hide; Hye-Ryun Kang; Allen P Kaplan; Constance H Katelaris; Sorena Kiani-Alikhan; Wei-Te Lei; Richard F Lockey; Hilary Longhurst; William Lumry; Andrew MacGinnitie; Alejandro Malbran; Inmaculada Martinez Saguer; Juan José Matta Campos; Alexander Nast; Dinh Nguyen; Sandra A Nieto-Martinez; Ruby Pawankar; Jonathan Peter; Grzegorz Porebski; Nieves Prior; Avner Reshef; Marc Riedl; Bruce Ritchie; Farrukh Rafique Sheikh; William B Smith; Peter J Spaeth; Marcin Stobiecki; Elias Toubi; Lilian Agnes Varga; Karsten Weller; Andrea Zanichelli; Yuxiang Zhi; Bruce Zuraw; Timothy Craig
Journal:  World Allergy Organ J       Date:  2022-04-07       Impact factor: 5.516

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.